Trials / Completed
CompletedNCT02371746
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Envisia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENV515-3 Travoprost XR | |
| DRUG | ENV515-1 Travoprost XR | |
| DRUG | ENV515-3-2 Travoprost XR |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2019-02-13
- Completion
- 2019-02-13
- First posted
- 2015-02-26
- Last updated
- 2019-10-17
- Results posted
- 2019-10-17
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02371746. Inclusion in this directory is not an endorsement.